Sampedro Camarena F, Cano Serral G, Sampedro Santaló F
Unidad de Investigación Oncológica, Hospital de la Santa Cruz y San Pablo, Barcelona, Spain.
Clin Transl Oncol. 2007 Mar;9(3):145-54. doi: 10.1007/s12094-007-0028-1.
This review will focus on the clinical utilities of telomerase for human cancer diagnosis and prognosis. Much attention has been focused on control of telomerase activity in early and late stage tumours. Telomerase stabilisation may be required for cells to escape replicative senescence and to proliferate indefinitely. Because of a very strong association between telomerase and malignancy, both clinicians and pathologists expect this molecule to be a useful diagnostic and prognostic marker and a new therapeutic target. These data have greatly inspired the development of various strategies to target telomere and telomerase for cancer therapy. Finally, evidence is now emerging that G-quadruplex ligands produce rapid senescence and selective cell death. A summary of recent experimental works with new small molecules as potential inhibitors of telomerase is presented.
本综述将聚焦于端粒酶在人类癌症诊断和预后方面的临床应用。在肿瘤的早期和晚期，人们对端粒酶活性的控制给予了极大关注。细胞逃脱复制性衰老并无限增殖可能需要端粒酶的稳定。由于端粒酶与恶性肿瘤之间存在非常紧密的关联，临床医生和病理学家都期望该分子成为有用的诊断和预后标志物以及新的治疗靶点。这些数据极大地推动了针对癌症治疗靶向端粒和端粒酶的各种策略的发展。最后，有证据表明，G-四链体配体可导致快速衰老和选择性细胞死亡。本文将对近期使用新型小分子作为端粒酶潜在抑制剂的实验工作进行总结。
